News and articles related to topics including Global Infectious Diseases: Prevention, Preparedness and Response and the China-US Relations conference.
International collaboration and innovative partnerships with industry, government, speeding bench-to-bedside discoveries
Whether it’s an inhaled therapeutic that stimulates innate immunity of the lungs to prevent the spread of bacterial and viral infections, or a novel tuberculosis test that allows doctors to diagnose the infectious disease within minutes, the partnerships between academic institutions, their spinoff companies, industry, and government are the driving force behind advancing these products to the market — and on faster timelines than ever before.
Disease outbreaks, such as the H5N1 avian influenza, H1N1 influenza pandemic of 2009, and more recently the Ebola outbreak in West Africa, exposed the need for quick access to high-quality, life-saving vaccines and therapeutics, and the importance of reliable, U.S.-based vaccine development and manufacturing capabilities and expertise.
Renaissance of natural products-based drug research gains momentum with international partnerships and a focus on anti-infective agents
While natural products form the basis of more than half of the therapeutic drugs on the market today, this research arena is experiencing a modern-day renaissance, thanks to advances in synthetic and analytic chemistry, as well as to the major advances in molecular biology and genomics.
New, rapid point-of-care TB test dramatically reduces the current delays in diagnosis with incredible accuracy, accelerating appropriate treatment and reducing the death rate of the highly infectious disease. Low-cost, easy-to-use test has the potential to eradicate TB.
The outbreak of the Ebola virus in Africa, and the role China and the U.S. are playing in dealing with emerging global infectious diseases, epidemic threats and bioterrorism, form the backdrop for the 6th George H.W. Bush China-U.S. Relations Conference, which will be held Monday, May 11, through Wednesday, May 13, 2015, at Hotel ZaZa in Houston, Texas.
There have to be solutions in place to protect global public health from infectious disease. Microbes respect no national boundaries, political affiliations, or ethnicities. These challenges extend far beyond our national borders. The fight against ebola is far from over, but the world needs to be prepared for the next outbreak. So how do we do it?
Ebola is a stark reminder that an outbreak anywhere can be a risk everywhere. This is both the harsh reality and the shining truth, but more than just managing this outbreak, we must learn from it and vow to prevent the next one by overcoming social, scientific and economic barriers that inhibit effective public health preparedness and response.
When a typical 100-bed hospital sees roughly 10-20 hospital-acquired infections a year it's no wonder "superbugs" like CRE or MRSA are top of mind. New study shows that manual disinfection combined with UV light can kill more than 90 percent of infection causing bacteria.
Biomedical research should ultimately benefit patients. That’s the driving force behind the work being done by LauraLee Hughes and her staff in the Texas A&M Health Science Center’s Office of Technology Translation (OTT).
April 3-11 is National Public Health Week. Jay Maddock, Ph.D., the new dean of the Texas A&M Health Science Center School of Public Health, offers some insight on the most pressing public health issues facing our state and nation.